Hemophilia Drugs Market Size By Application, Industry Analysis Report, Regional Outlook (North America, Europe, Asia Pacific, Middle East & Africa, And South America), Growth Potential, Price Trends, Competitive Market Share & Forecast 2023 - 2030 (Recession Impact Analysis)
ID : MRU_
1828 | Date :
Jan, 2023 | Pages :
168 | Region : Global |
Publisher : 99 Strategy
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab\' by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate\' for type A and ‘Aprolix\' for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market\'s growth over the forecast period.
The Americas led the global hemophilia drugs market in 2019 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market\'s growth in the region.
The Global Hemophilia Drugs Market touched xxx million USD with a CAGR xx % from 2018-2022 around the world. In the future, it is predicted to reach xxx million USD in 2023 with a CAGR xx % from 2023-2030.
As the report focuses on global Hemophilia Drugs Market, mainly in Europe and Asia Pacific, North America, Middle East and Africa, and South America. This report segmented the Market on the basis of regions, manufacturers, applications, and type.
in addition, this report introduces Market competition situation among the vendors and company profile, besides, Market price analysis and value chain features are covered in this report.
In Market segmentation by manufacturers, the report covers the following companies-
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
In Market segmentation by geographical regions, the report has analyzed the following regions- North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Columbia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
In Market segmentation by types covers:
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
In Market segmentation by applications :
Recombinant Therapies
Plasma-Derived Therapies
Apart from the drivers, restraints, and opportunities, the report also offers competitive landscape, including various growth strategies adopted by profiled players for establishing significant position in the industry. The segmentation included in the comprehensive report will help respectable manufacturers to set up their processing units in the regions and increase their global presence. This would also benefit the industry and increase the company\'s product portfolio.
The research provides answers to the following key questions:
• What is the estimated growth rate and Market share and size of the Hemophilia Drugs Market for the forecast period 2023-2030?
• What are the driving forces in the Hemophilia Drugs Market for the forecast period 2023-2030?
• Who are the prominent Market players and how have they gained a competitive edge over other competitors?
• What are the Market trends influencing the progress of the Hemophilia Drugs industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the Market hold for the prominent Market players? Any special requirements about this report, please let us know and we can provide custom report.
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Hemophilia Drugs Market Size Growth Rate by Type (2020-2030)
1.3.2 Hemophilia A
1.3.3 Inhibitors
1.3.4 Hemophilia B
1.3.5 Von Willebrand Disease
1.4 Market Segment by Application
1.4.1 Global Hemophilia Drugs Market Share by Application (2020-2030)
1.4.2 Recombinant Therapies
1.4.3 Plasma-Derived Therapies
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemophilia Drugs Market Size
2.1.1 Global Hemophilia Drugs Revenue 2015-2030
2.1.2 Global Hemophilia Drugs Sales 2015-2030
2.2 Hemophilia Drugs Growth Rate by Regions
2.2.1 Global Hemophilia Drugs Sales by Regions 2018 - 2022
2.2.2 Global Hemophilia Drugs Revenue by Regions 2018 - 2022
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Hemophilia Drugs Sales by Manufacturers
3.1.1 Hemophilia Drugs Sales by Manufacturers 2018 - 2022
3.1.2 Hemophilia Drugs Sales Market Share by Manufacturers 2018 - 2022
3.2 Revenue by Manufacturers
3.2.1 Hemophilia Drugs Revenue by Manufacturers (2018 - 2022)
3.2.2 Hemophilia Drugs Revenue Share by Manufacturers (2018 - 2022)
3.2.3 Global Hemophilia Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Hemophilia Drugs Price by Manufacturers
3.4 Key Manufacturers Hemophilia Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Hemophilia Drugs Market
3.6 Key Manufacturers Hemophilia Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Hemophilia A Sales and Revenue (2018 - 2022)
4.1.2 Inhibitors Sales and Revenue (2018 - 2022)
4.1.3 Hemophilia B Sales and Revenue (2018 - 2022)
4.1.4 Von Willebrand Disease Sales and Revenue (2018 - 2022)
4.2 Global Hemophilia Drugs Sales Market Share by Type
4.3 Global Hemophilia Drugs Revenue Market Share by Type
4.4 Hemophilia Drugs Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Hemophilia Drugs Sales by Application
6 United States
6.1 United States Hemophilia Drugs Breakdown Data by Company
6.2 United States Hemophilia Drugs Breakdown Data by Type
6.3 United States Hemophilia Drugs Breakdown Data by Application
7 European Union
7.1 European Union Hemophilia Drugs Breakdown Data by Company
7.2 European Union Hemophilia Drugs Breakdown Data by Type
7.3 European Union Hemophilia Drugs Breakdown Data by Application
8 China
8.1 China Hemophilia Drugs Breakdown Data by Company
8.2 China Hemophilia Drugs Breakdown Data by Type
8.3 China Hemophilia Drugs Breakdown Data by Application
9 Rest of World
9.1 Rest of World Hemophilia Drugs Breakdown Data by Company
9.2 Rest of World Hemophilia Drugs Breakdown Data by Type
9.3 Rest of World Hemophilia Drugs Breakdown Data by Application
9.4 Rest of World Hemophilia Drugs Breakdown Data by Countries
9.4.1 Rest of World Hemophilia Drugs Sales by Countries
9.4.2 Rest of World Hemophilia Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Baxalta
10.1.1 Baxalta Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.1.4 Hemophilia Drugs Product Introduction
10.1.5 Baxalta Recent Development
10.2 Bayer
10.2.1 Bayer Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.2.4 Hemophilia Drugs Product Introduction
10.2.5 Bayer Recent Development
10.3 CSL Behring
10.3.1 CSL Behring Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.3.4 Hemophilia Drugs Product Introduction
10.3.5 CSL Behring Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.4.4 Hemophilia Drugs Product Introduction
10.4.5 Pfizer Recent Development
10.5 Alnylam Pharmaceuticals
10.5.1 Alnylam Pharmaceuticals Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.5.4 Hemophilia Drugs Product Introduction
10.5.5 Alnylam Pharmaceuticals Recent Development
10.6 BioMarin
10.6.1 BioMarin Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.6.4 Hemophilia Drugs Product Introduction
10.6.5 BioMarin Recent Development
10.7 Catalyst Biosciences
10.7.1 Catalyst Biosciences Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.7.4 Hemophilia Drugs Product Introduction
10.7.5 Catalyst Biosciences Recent Development
10.8 Dimension Therapeutics
10.8.1 Dimension Therapeutics Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.8.4 Hemophilia Drugs Product Introduction
10.8.5 Dimension Therapeutics Recent Development
10.9 F. Hoffmann-La Roche
10.9.1 F. Hoffmann-La Roche Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.9.4 Hemophilia Drugs Product Introduction
10.9.5 F. Hoffmann-La Roche Recent Development
10.10 Grifols
10.10.1 Grifols Company Details
10.10.2 Company Description and Business Overview
10.10.3 Sales, Revenue and Market Share of Hemophilia Drugs
10.10.4 Hemophilia Drugs Product Introduction
10.10.5 Grifols Recent Development
10.11 Octapharma
10.12 Sangamo Biosciences
10.13 Spark Therapeutics
10.14 Swedish Orphan Biovitrum
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Hemophilia Drugs Sales Channels
11.2.2 Hemophilia Drugs Distributors
11.3 Hemophilia Drugs Customers
12 Market Forecast
12.1 Global Hemophilia Drugs Sales and Revenue Forecast 2020-2030
12.2 Global Hemophilia Drugs Sales Forecast by Type
12.3 Global Hemophilia Drugs Sales Forecast by Application
12.4 Hemophilia Drugs Forecast by Regions
12.4.1 Global Hemophilia Drugs Sales Forecast by Regions 2020-2030
12.4.2 Global Hemophilia Drugs Revenue Forecast by Regions 2020-2030
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
Research Methodology
The Market Research Update offers technology-driven solutions and its full integration in the research process to be skilled at every step. We use diverse assets to produce the best results for our clients. The success of a research project is completely reliant on the research process adopted by the company. Market Research Update assists its clients to recognize opportunities by examining the global market and offering economic insights. We are proud of our extensive coverage that encompasses the understanding of numerous major industry domains.
Market Research Update provide consistency in our research report, also we provide on the part of the analysis of forecast across a gamut of coverage geographies and coverage. The research teams carry out primary and secondary research to implement and design the data collection procedure. The research team then analyzes data about the latest trends and major issues in reference to each industry and country. This helps to determine the anticipated market-related procedures in the future. The company offers technology-driven solutions and its full incorporation in the research method to be skilled at each step.
The Company's Research Process Has the Following Advantages:
Information Procurement
The step comprises the procurement of market-related information or data via different methodologies & sources.
Information Investigation
This step comprises the mapping and investigation of all the information procured from the earlier step. It also includes the analysis of data differences observed across numerous data sources.
Highly Authentic Source
We offer highly authentic information from numerous sources. To fulfills the client’s requirement.
Market Formulation
This step entails the placement of data points at suitable market spaces in an effort to assume possible conclusions. Analyst viewpoint and subject matter specialist based examining the form of market sizing also plays an essential role in this step.
Validation & Publishing of Information
Validation is a significant step in the procedure. Validation via an intricately designed procedure assists us to conclude data-points to be used for final calculations.
We are flexible and responsive startup research firm. We adapt as your research requires change, with cost-effectiveness and highly researched report that larger companies can't match.
Information Safety
Market Research Update ensure that we deliver best reports. We care about the confidential and personal information quality, safety, of reports. We use Authorize secure payment process.
We Are Committed to Quality and Deadlines
We offer quality of reports within deadlines. We've worked hard to find the best ways to offer our customers results-oriented and process driven consulting services.
Our Remarkable Track Record
We concentrate on developing lasting and strong client relationship. At present, we hold numerous preferred relationships with industry leading firms that have relied on us constantly for their research requirements.
Best Service Assured
Buy reports from our executives that best suits your need and helps you stay ahead of the competition.
Customized Research Reports
Our research services are custom-made especially to you and your firm in order to discover practical growth recommendations and strategies. We don't stick to a one size fits all strategy. We appreciate that your business has particular research necessities.
Service Assurance
At Market Research Update, we are dedicated to offer the best probable recommendations and service to all our clients. You will be able to speak to experienced analyst who will be aware of your research requirements precisely.
